Please ensure Javascript is enabled for purposes of website accessibility

Why Haemonetics Stock Fell 13% Today

By Eric Volkman - May 13, 2021 at 6:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors don't seem to be buying the company's rosy 2022 guidance.

What happened

Investors were not kind to Haemonetics (HAE) on Thursday, trading the stock down by more than 13%. The sell-off occurred in the wake of the blood and plasma collection systems company's 2021 earnings release for the fiscal fourth quarter of 2021.

So what

The quarter saw Haemonetics earn $221 million in revenue, down 6% on a year-over-year basis. Non-GAAP (adjusted) net income also went south, declining by almost 33% to $23.9 million, or $0.46.

Medical professionals walking in the hallway of a hospital.

Image source: Getty Images.

This meant a mixed quarter for the healthcare company, as analysts tracking the stock were modeling just under $223 million on the top line and $0.67 for adjusted, per-share net income.

Haemonetics blamed the declines on the coronavirus pandemic, which particularly affected its business related to plasma. However, the company quoted its CEO Chris Simon as saying that "We remain confident in the strong end-market demand for our products and expect full recovery from the pandemic by the end of this fiscal year."

Now what

Reflecting this, Haemonetics is counting on notable growth for its fiscal 2022. The company proffered guidance indicating that total revenue will increase organically by 8% to 12%, with adjusted earnings per share coming in at $2.60 to $3 (2021 result: $2.35).

The company's business should improve now that the coronavirus pandemic is receding, with would-be patients scheduling the procedures many postponed during the outbreak. The market's reaction to the earnings release, however, indicates that investors are skeptical about Haemonetics' optimistic 2022 forecasts.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Haemonetics Corporation Stock Quote
Haemonetics Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.